MedTrace Logo

Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients

NCT02252328 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-10-26

No results posted yet for this study

Summary

The trial will compare the effect on disease control and immunosuppression treatment of adding simvastatin 80mg once daily, over a follow-up and treatment period of 2 years. Patients will be randomised in a 1:1 fashion to standard treatment with placebo or standard treatment with the addition of simvastatin (80mg daily). They will be followed at 3 months intervals for 2 years with a primary end point of mean reduction in corticosteroid dosage at the 12 month follow-up visit.

Conditions

  • Uveitis

Interventions

DRUG

Simvastatin

Simvastatin 80mg once daily

DRUG

Placebo

Placebo tablets once daily

Sponsors & Collaborators

  • University College, London

    lead OTHER

Principal Investigators

  • Oren Tomkins-Netzer, MD, PhD · University College, London

  • Sue Lightman, PhD,FRCOphth · University College, London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2018-08-31
Completion
2019-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02252328 on ClinicalTrials.gov